*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
In her ‘Inside the City’ column for the Sunday Times this week, Sabah Meddings opened by saying the story of Motif Bio was a familiar one - a drug development firm promising a blockbuster treatment for an underserved disease “crashes at the final hurdle”.
In her ‘Inside the City’ column for the Sunday Times, Sabah Meddings was focussed this week on upstart online property portal OnTheMarket, and its hastening plans to reach profitability.
Shares tips from the Sunday newspapers, including Centamin in the Sunday Times, Nanoco in the Mail on Sunday and Sunday Telegraph with Johnson Matthey.
